Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of [14C]-Iberdomide in Healthy Males
NCT03294603Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iberdomide in systemic lupus erythematosus (SLE) and multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Pharmacokinetics - Total [14C]-Radioactivity (RA), Pharmacokinetics - Cumulative excretion of total [14C]-RA and 6 more. Started Sep 2017; status: completed.
02
Drugs
iberdomide
03
Conditions
systemic lupus erythematosus (SLE)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03294603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03294603.